BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 231 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2020. The put-call ratio across all filers is 0.22 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $10,609,000 | +3.8% | 70,176 | 0.0% | 0.43% | +8.0% |
| Q2 2022 | $10,225,000 | +22.9% | 70,176 | 0.0% | 0.40% | +37.7% |
| Q1 2022 | $8,321,000 | -14.0% | 70,176 | 0.0% | 0.29% | -6.1% |
| Q4 2021 | $9,671,000 | -23.3% | 70,176 | -22.7% | 0.31% | -23.4% |
| Q3 2021 | $12,613,000 | +466.1% | 90,799 | +164.9% | 0.41% | +389.2% |
| Q3 2020 | $2,228,000 | -11.1% | 34,277 | 0.0% | 0.08% | -12.6% |
| Q2 2020 | $2,506,000 | +63.0% | 34,277 | -24.1% | 0.10% | +37.7% |
| Q1 2020 | $1,537,000 | -3.1% | 45,164 | +55.1% | 0.07% | +15.0% |
| Q4 2019 | $1,586,000 | +30.5% | 29,125 | 0.0% | 0.06% | +13.2% |
| Q3 2019 | $1,215,000 | -71.0% | 29,125 | -82.1% | 0.05% | -67.5% |
| Q1 2018 | $4,185,000 | – | 162,477 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
| Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
| ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
| DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
| Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
| Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |